ArticleBMC cancer2025
Efficacy and safety of first-line chemoimmunotherapy in young patients with extensive-stage small cell lung cancer: a multicenter retrospective study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesChemoimmunotherapy is the first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). This study aims to evaluate the survival outcomes and safety of chemoimmunotherapy in young patients with ES-SCLC. PATIENTS AND
methodsPatients with pathologically or cytologically confirmed ES-SCLC from three centers and divided into two age groups: young (aged ≤ 45 years) and control (aged > 45 to ≤ 75 years) between January 2015 and December 2023. We assessed progression-free survival (PFS), overall survival (OS), and safety between the two age groups.
resultsOf the whole 347 patients, 59 were in the young group, while 288 were in the control group. The young group exhibited poorer PFS (median, 4.67 vs. 5.40 months, p < 0.001) and OS (median, 13.7 vs. 14.4 months, p = 0.028) compared with the control group, particularly in the context of chemoimmunotherapy [PFS (median, 4.50 vs. 5.57 months; p = 0.002), OS (median, 13.20 vs. 15.33 months; p = 0.012), respectively]. Additionally, in the young group, chemoimmunotherapy showed similar PFS (median, 4.50 vs. 5.75 months; p = 0.501) and OS (median, 13.20 vs. 13.70 months; p = 0.508) compared to chemotherapy. Moreover, the young group had a higher incidence of immune-related adverse events (irAEs) (30.51% vs. 11.46%, p < 0.001) and hematologic toxicity, including thrombocytopenia (25.42% vs. 14.24%, p = 0.033).
conclusionsThe young group had poorer survival outcomes and chemoimmunotherapy may not provide a survival benefit in young patients, as evidenced by similar PFS and OS compared to chemotherapy. Additionally, the young group also experienced a higher incidence of immune-related adverse events (irAEs) and hematologic toxicity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.